Reuters logo
BRIEF-Mallinckrodt to acquire Ocera Therapeutics and OCR-002, its proprietary therapy
2017年11月2日 / 上午11点00分 / 17 天前

BRIEF-Mallinckrodt to acquire Ocera Therapeutics and OCR-002, its proprietary therapy

Nov 2 (Reuters) - Mallinckrodt Plc

* Mallinckrodt to acquire Ocera Therapeutics and OCR-002, its proprietary therapy in development for treatment of hepatic encephalopathy

* Mallinckrodt Plc - ‍Mallinckrodt to commence cash tender offer to purchase ocera therapeutics for $1.52 per share, plus contingent value right​

* Mallinckrodt Plc - ‍Assuming expected 2017 deal close, expects dilution from deal to adjusted EPS of about $0.25 to $0.35 annually beginning in 2018​

* Mallinckrodt Plc - Expects dilution from acquisition to adjusted diluted earnings per share by $0.25 to $0.35 annually beginning in 2018​

* Mallinckrodt - Deal includes ‍contingent value right in cash up to $2.58/share based on successful completion of some development and sales milestones​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below